| Autor: |
A, Levy, J, Doyen, A, Botticella, R, Bourdais, S, Achkar, P, Giraud, C, Du, C, Naltet, P, Lavaud, B, Besse, P, Pradère, O, Mercier, C, Caramella, D, Planchard, E, Deutsch, C, Le Péchoux |
| Jazyk: |
francouzština |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique. 24(1) |
| ISSN: |
1769-6658 |
| Popis: |
Concomitant radiochemotherapy has been the standard of care for unresectable stage III non-small cell lung cancer (NSCLC), irrespective of histological sub-type or molecular characteristics. Currently, only 15-30 % of patients are alive five years after radiochemotherapy, and this figure remains largely unchanged despite multiple phase III randomised trials. In recent years, immune-checkpoint blockades with anti-PD-(L)1 have revolutionised the care of metastatic NSCLC, becoming the standard front- and second-line strategy. Several preclinical studies reported an increased tumour antigen release, improved antigen presentation, and T-cell infiltration in irradiated tumours. Immunotherapy has therefore recently been evaluated for patients with locally advanced stage III NSCLC. Following the PACIFIC trial, the anti-PD-L1 durvalumab antibody has emerged as a new standard consolidative treatment for patients with unresectable stage III NSCLC whose disease has not progressed following concomitant platinum-based chemoradiotherapy. Immunoradiotherapy therefore appears to be a promising association in patients with localised NSCLC. Many trials are currently evaluating the value of concomitant immunotherapy and chemoradiotherapy and/or consolidative chemotherapy with immunotherapy in patients with locally advanced unresectable NSCLC. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect